borderline significanceP = 0.069
For patients with primary tumors, Her2 staining discriminated survival with borderline significance (Log-rank test, P = 0.069), with Her2 negative patients having a worse outcome.
For patients with primary tumors, Her2 staining discriminated survival with borderline significance (Log-rank test, P = 0.069), with Her2 negative patients having a worse outcome.
Compared to patients with tumors negative for Her3, patients with tumors positive for Her3 showed a trend toward worse survival irrespective of Her2 staining result.